AstraZeneca Plots Next Steps in Covid Effort With U.K. Lab
- Covid labs will be housed in new Cambridge research base
- CEO said Covid shot could be behind U.K. doing better than EU
This article is for subscribers only.
AstraZeneca Plc will open labs for its Covid-19 products at a new U.K. research and development site this year as the drugmaker defends its vaccine’s effectiveness against doubts at home.
The labs, which will be based at the R&D hub in Cambridge, England opened Tuesday, will house a unit for vaccines and also focus on the company’s antibody cocktail, which is expected to receive U.S. and U.K. authorization in coming months.